Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28657073 | 0.97 | CYP2C19 (0.33) | CYP2C19KMT2AMIFLMNAHSD17B10 | |
| Ammonia Solution, Strong SCHEMBL27557378 | 0.97 | CYP2C19 (0.33) | CYP2C19KMT2AMIFLMNAHSD17B10 | |
| SCHEMBL1070160 | 0.85 | — | — | |
| SCHEMBL7720073 | 0.84 | SERPINE1 (0.39) | LMNAHSD17B10ADRA2AADRA1AMGAM | |
| SCHEMBL2485813 | 0.81 | ADRA2A (0.42) | CYP2C19KMT2AMIFLMNAHSD17B10 | |
| SCHEMBL722025 | 0.81 | GAA (0.50) | CYP2C19KMT2AMIFLMNAHSD17B10 | |
| SCHEMBL28292486 | 0.80 | CYP4F2 (0.33) | CYP2C19KMT2AMIFADRA2AADRA1A | |
| SCHEMBL15892076 | 0.80 | SERPINE1 (0.33) | — | |
| SCHEMBL28570727 | 0.80 | THRB (0.37) | CYP2C19HSD17B10ADRA2AADRA1AMAPT | |
| SCHEMBL12028701 | 0.79 | LMNA (0.35) | CYP2C19KMT2AMIFLMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3560934-A1 | PROCESS FOR THE PREPARATION OF PURE 2-CYANOPHENYLBORONIC ACID AND ESTERS THEREOF, INTERMEDIATES OF PERAMPANEL OR OF E2040 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2019-10-30 | — | — | EP | claimed |
| US-20230150919-A1 | Method for Producing Mono-Cross-Coupled Aromatic Compound Having Leaving Group | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2023-05-18 | — | — | US | disclosed |
| EP-4116282-A1 | METHOD FOR PRODUCING MONO-CROSS-COUPLED AROMATIC COMPOUND HAVING LEAVING GROUP | National University Corporation Hokkaido University (JP) | 2023-01-11 | — | — | EP | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| CN-114630835-A | Process for the preparation of peptide compounds comprising sterically bulky amino acids | 中外制药株式会社 | 2022-06-14 | — | — | CN | disclosed |
| US-20210387994-A1 | SOLVENT-FREE CROSS-COUPLING REACTION, AND PRODUCTION METHOD USING SAID REACTION | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2021-12-16 | — | — | US | disclosed |
| CN-105829307-B | Tetrahydroimidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2020-07-24 | — | — | CN | disclosed |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2020-05-14 | — | — | US | disclosed |
| EP-3560934-A1 | PROCESS FOR THE PREPARATION OF PURE 2-CYANOPHENYLBORONIC ACID AND ESTERS THEREOF, INTERMEDIATES OF PERAMPANEL OR OF E2040 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2019-10-30 | — | — | EP | disclosed |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20050143369-A1 | Gamma-secretase inhibitors | MERCK SHARP & DOHME LTD. (GB) | 2005-06-30 | — | — | US | disclosed |
| US-6908692-B1 | Electrically conductive wire with curable coating including reactive particles based on element-oxygen network and binder which reacts with particle; cures to inorganic-organic-oxygen network with high partial discharge resistance | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2005-06-21 | — | — | US | disclosed |
| WO-2005030731-A1 | GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME LIMITED (GB) | 2005-04-07 | — | — | WO | disclosed |
| EP-1503998-A1 | HETEROARYL SUBSTITUTED SPIROCYCLIC SUFAMIDES FOR INHIBITION OF GAMMA SECRETASE | MERCK SHARP & DOHME LTD. (GB) | 2005-02-09 | — | — | EP | disclosed |
| US-6849822-B2 | Coating composition for metal conductors and coating process involving the use thereof | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040159634-A1 | Coating composition for metal conductors and coating process involving the use thereof | E.I. DU PONT DE NEMOURS AND COMPANY | 2004-08-19 | — | — | US | disclosed |
| WO-2003093252-A1 | HETEROARYL SUBSTITUTED SPIROCYCLIC SULFAMIDES FOR INHIBITION OF GAMMA SECRETASE | MERCK SHARP & DOHME LIMITED (GB) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003057786-A1 | COATING COMPOSITION FOR METAL CONDUCTORS AND COATING PROCESS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030129396-A1 | Coating composition for metal conductors and coating process involving the use thereof | E.I. DU PONT DE NEMOURS AND COMPANY | 2003-07-10 | — | — | US | disclosed |
| US-5106625-A | Transparent, extendible, adhesive, retentive | KAO CORPORATION (JP) | 1992-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CYP2C19 1029/4885KMT2A 2475/4885MIF 349/4885 |
| US-20230150919-A1 | Method for Producing Mono-Cross-Coupled Aromatic Compound Having Leaving Group | DDC, PAH, ATIC | CYP2C19 364/4885KMT2A 357/4885MIF 4456/4885 |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CYP2C19 1029/4885KMT2A 2475/4885MIF 349/4885 |
| US-20210387994-A1 | SOLVENT-FREE CROSS-COUPLING REACTION, AND PRODUCTION METHOD USING SAID REACTION | MCCC2, CTRC, DDC | CYP2C19 283/4885KMT2A 2354/4885MIF 4848/4885 |
| US-20050143369-A1 | Gamma-secretase inhibitors | BACE1, BACE2, PSEN1 | CYP2C19 3520/4885KMT2A 3046/4885MIF 3194/4885 |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | CYP2C19 1029/4885KMT2A 2475/4885MIF 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.